Financial Data and Key Metrics Changes - UnitedHealth Group reported revenues of nearly $112 billion for the second quarter, a 13% increase year-over-year, but adjusted earnings per share of $4.08 fell below the previous year due to pricing and medical cost trends [50][52] - The full year 2025 outlook anticipates revenues approaching $448 billion, reflecting an 11% growth over 2024, with a medical care ratio of 89.25% plus or minus 25 basis points, up from an initial 86.5% midpoint [57][58] Business Line Data and Key Metrics Changes - UnitedHealthcare's second quarter revenues grew by over $12 billion to $86.1 billion, while operating earnings declined by $1.9 billion to $2.1 billion due to medical trend factors [52] - OptumHealth revenues were $25.2 billion in the second quarter, a decline of $1.8 billion from last year, driven by contract adjustments and Medicare funding reductions [54] - OptumRx experienced a revenue growth of $6 billion or 19% year-over-year, driven by new customer additions and specialty products [56] Market Data and Key Metrics Changes - The Medicare Advantage growth year-to-date is 650,000 people, including those eligible for both Medicaid and Medicare [52] - The commercial offerings are experiencing less member growth than initially anticipated, with ACA exchange driving about one-third of the reduced commercial risk member growth outlook for 2025 [53] Company Strategy and Development Direction - The company is undergoing a cultural shift to enhance engagement with regulators and stakeholders, aiming to modernize its operations and improve consumer experiences through technology [8][9] - A focus on margin recovery and operational discipline is emphasized, with significant adjustments to benefits and pricing strategies planned for 2026 [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged unprecedented medical cost trends and the need for a fundamental reorientation of certain business lines to address these challenges [9][10] - The outlook for 2026 anticipates solid but moderate earnings growth, with expectations for stronger growth in 2027 and beyond [62] Other Important Information - The company has recognized approximately $6.5 billion more in medical costs than initially anticipated for 2025, with significant impacts across Medicare, commercial, and Medicaid segments [13][14] - The operational and pricing strategies reflect an understanding of the challenges faced, with a commitment to navigate financial pressures responsibly [26][27] Q&A Session Summary Question: Insights on OptumHealth's pricing and margin expectations - Management confirmed that pricing adjustments from payers will positively impact capitation rates for OptumHealth, which is expected to mitigate 50% of the V28 headwind [66] Question: Run rate earnings expectations for 2026 - The assessment indicated a reasonable expectation of around $13 of run rate earnings, with significant impacts from premium revenue repricing on January 1 [71][76] Question: Long-term EPS growth outlook - The long-term EPS growth rate is expected to return to low double-digit ranges, with a framework for growth remaining intact despite current challenges [80][81]

Financial Data and Key Metrics Changes - UnitedHealth Group reported revenues of nearly $112 billion for the second quarter, a 13% increase year-over-year, but adjusted earnings per share of $4.08 fell below the previous year due to pricing and medical cost trends [52][54] - The full year 2025 outlook anticipates revenues approaching $448 billion, reflecting an 11% growth over 2024, with a medical care ratio of 89.25% plus or minus 25 basis points, up from the initial 86.5% midpoint [58][59] Business Line Data and Key Metrics Changes - UnitedHealthcare's second quarter revenues grew by over $12 billion to $86.1 billion, while operating earnings declined by $1.9 billion to $2.1 billion due to medical trend factors [54] - OptumHealth revenues were $25.2 billion in the second quarter, a decline of $1.8 billion from last year, driven by contract adjustments and Medicare funding reductions [56] - OptumRx second quarter revenues grew by $6 billion or 19% year-over-year to $38.5 billion, driven by new customer additions and specialty products [56] Market Data and Key Metrics Changes - The Medicare Advantage growth year-to-date is 650,000 people, including those eligible for both Medicaid and Medicare [54] - The commercial offerings are experiencing less member growth than initially anticipated, with ACA exchange driving about one-third of the reduced commercial risk member growth outlook for 2025 [55] Company Strategy and Development Direction - The company is undergoing a cultural shift to improve relationships with regulators and stakeholders, focusing on transparency and accountability [6][9] - A pricing strategy is being implemented to recover margins and return to earnings growth targets, particularly in Medicare, with adjustments to benefits and product offerings [22][23] - The company is committed to improving operational disciplines and leveraging technology, including AI, to enhance efficiency and reduce costs [45][46] Management's Comments on Operating Environment and Future Outlook - Management acknowledged significant challenges due to underestimated medical costs and pricing errors, particularly in the Medicare portfolio, but expressed confidence in resolving these issues and recapturing earnings growth potential [12][14] - The outlook for 2026 anticipates solid but moderate earnings growth, with expectations for stronger growth in 2027 and beyond [64][65] Other Important Information - The company has made extensive management and operational changes to align with its reform agenda, including leadership changes and a focus on improving execution [11][30] - The operational and pricing strategies reflect an understanding of the challenges faced by the company and a commitment to navigating financial pressures responsibly [28][29] Q&A Session Summary Question: Discussion on OptumHealth's pricing and margin expectations - Management confirmed that pricing adjustments from UnitedHealthcare and other payers will positively impact capitation rates for OptumHealth, helping to mitigate headwinds from funding cuts [69][70] Question: Run rate earnings and EPS growth drivers - Management indicated that the second half of 2025 is expected to show a run rate of around $13 in earnings, with significant impacts from premium revenue repricing in January 2026 [76][79] Question: Long-term EPS growth rate and margin targets - Management expects to return to low double-digit growth rates in the long term, with no significant changes to targeted margin ranges across UnitedHealthcare and Optum segments [81][85] Question: Portfolio actions and their impact on earnings - Management clarified that portfolio actions were reevaluated, and some previously planned actions were paused, which may affect future earnings power [89][91]

Core Viewpoint - UnitedHealth Group reported quarterly earnings of $4.08 per share, missing the Zacks Consensus Estimate of $4.84 per share, and down from $6.8 per share a year ago, indicating an earnings surprise of -15.70% [1][2] Financial Performance - The company posted revenues of $111.62 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.06%, and up from $98.86 billion year-over-year [2] - Over the last four quarters, UnitedHealth has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - UnitedHealth shares have declined approximately 44.2% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for UnitedHealth is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.93 on revenues of $113.13 billion, and for the current fiscal year, it is $21.15 on revenues of $448.53 billion [7] - The trend of estimate revisions for UnitedHealth was unfavorable prior to the earnings release, which may impact future stock movements [5][6] Industry Context - The Medical - HMOs industry, to which UnitedHealth belongs, is currently in the bottom 4% of the Zacks industry rankings, suggesting potential challenges ahead [8] - The performance of UnitedHealth's stock may be influenced by the overall outlook for the industry [8]

Company Overview - UnitedHealth Group reported a profit decline to $3.4 billion in the second quarter due to rising costs associated with providing health insurance to millions of Americans [2][3] - The company has reinstated Stephen Hemsley as CEO and anticipates a return to earnings growth in 2026 [3] Financial Outlook - UnitedHealth Group updated its 2025 financial outlook, projecting revenues between $445.5 billion and $448.0 billion, with net earnings of at least $14.65 per share and adjusted earnings of at least $16 per share [4] - The revised outlook is below some analysts' expectations and reflects the performance of the first half of 2025 along with anticipated care trends [4] Operational Challenges - The consolidated medical care ratio for UnitedHealthcare increased to 89.4%, up 430 basis points year-over-year, compared to 84.8% in the previous year [7] - The rise in the medical cost ratio is attributed to medical cost trends surpassing pricing trends, including unit costs and service intensity, as well as ongoing Medicare funding reductions [8] Industry Context - UnitedHealth's cost management struggles are part of a broader trend affecting health insurance companies over the past two years, particularly those managing government-subsidized plans [9] - Other companies in the industry, such as Centene and Elevance Health, have also reported challenges in controlling costs and have adjusted their profit forecasts downward due to similar pressures [10][11]

UnitedHealthcare signage is displayed on an office building in Phoenix, Arizona, on July 19, 2023. Shares of UnitedHealth Group fell more than 3% in premarket trading on Tuesday. UnitedHealth Group's report signals that elevated medical costs in Medicare Advantage plans may not ease anytime soon for the broader health insurance industry. UnitedHealthcare, the insurance arm of UnitedHealth Group, is the nation's largest provider of those privately run Medicare plans. Higher expenses in Medicare Advantage pla ...

[Executive Summary & 2025 Outlook Re-establishment](index=1&type=section&id=Executive%20Summary%20%26%202025%20Outlook%20Re-establishment) [Overall Company Performance and Strategic Direction](index=1&type=section&id=Overall%20Company%20Performance%20and%20Strategic%20Direction) UnitedHealth Group re-established its full-year 2025 outlook after a temporary suspension, reflecting first-half performance and anticipated care trends, aiming for a rigorous path back to high performance and strengthening operating disciplines for growth in 2026 and beyond, while continuing to support patients, physicians, and customers - UnitedHealth Group re-established its **2025 outlook**, previously suspended on **May 13, 2025**, reflecting first-half performance and higher realized/anticipated care trends[3](index=3&type=chunk) - The company expects to return to earnings growth in **2026**, focusing on strengthening operating disciplines[3](index=3&type=chunk) [UnitedHealth Group 2025 Outlook](index=1&type=section&id=UnitedHealth%20Group%202025%20Outlook) The updated full-year 2025 outlook projects revenues between $445.5 billion and $448.0 billion, with net earnings of at least $14.65 per share and adjusted earnings of at least $16.00 per share, with Optum and UnitedHealthcare expected to contribute significantly to these figures UnitedHealth Group 2025 Outlook ($ in millions, except per share data) | UnitedHealth Group 2025 Outlook ($ in millions, except per share data) | Revenue | Operating Earnings | | :--- | :--- | :--- | | Optum | $266,000 - $267,500 | $12,550 - $12,850 | | UnitedHealthcare | $344,000 - $345,500 | $9,000 - $9,300 | | Eliminations | ($164,500) - ($165,000) | — | | Total UnitedHealth Group | $445,500 - $448,000 | $21,550 - $22,150 | | | Diluted | Adjusted (a) | | Net Earnings per Share | At least $14.65 | At least $16.00 | - Full Year **2025** Revenue Outlook is **$445.5 Billion** to **$448.0 Billion**[6](index=6&type=chunk) - Full Year **2025** Earnings Outlook is at least **$14.65 Per Share**, with Adjusted Earnings of at least **$16.00 Per Share**[6](index=6&type=chunk) [Consolidated Financial Performance - Second Quarter 2025](index=2&type=section&id=Consolidated%20Financial%20Performance%20-%20Second%20Quarter%202025) [Key Financial Highlights](index=2&type=section&id=Key%20Financial%20Highlights) UnitedHealth Group reported second quarter 2025 revenues of $111.6 billion, a $12.8 billion year-over-year increase, though earnings from operations decreased to $5.2 billion and net margin declined to 3.1%, impacted by unfavorable discrete items and higher medical cost trends Quarterly Financial Performance (Consolidated) | Quarterly Financial Performance | June 30, 2025 | June 30, 2024 | March 31, 2025 | | :--- | :--- | :--- | :--- | | Revenues | $111.6 billion | $98.9 billion | $109.6 billion | | Earnings from Operations | $5.2 billion | $7.9 billion | $9.1 billion | | Net Margin | 3.1% | 4.3% | 5.7% | - Second quarter **2025** revenues grew **$12.8 billion** year-over-year to **$111.6 billion**, driven by growth in UnitedHealthcare and Optum[7](index=7&type=chunk) - Second quarter earnings from operations were **$5.2 billion**, and adjusted net earnings were **$4.08 per share**, including **$1.2 billion** of unfavorable discrete impacts[7](index=7&type=chunk) [Operational Metrics and Trends](index=2&type=section&id=Operational%20Metrics%20and%20Trends) The consolidated medical care ratio increased significantly to 89.4% due to medical cost trends exceeding pricing and Medicare funding reductions, while the operating cost ratio improved to 12.3%, benefiting from business mix changes and reduced cyberattack impacts, and the company increased its quarterly dividend by 5% and returned $4.5 billion to shareholders - The second quarter consolidated medical care ratio increased **430 basis points** year-over-year to **89.4%**, primarily due to medical cost trends significantly exceeding pricing trends and Medicare funding reductions[7](index=7&type=chunk) - The second quarter **2025** operating cost ratio improved to **12.3%** (vs. **13.3%** YoY), reflecting business mix, reduced impacts from the Change Healthcare cyberattack, and cost management activities[7](index=7&type=chunk) - The company increased its quarterly dividend rate by **5%** to **$2.21** and returned **$4.5 billion** to shareholders through dividends and share repurchases in **Q2 2025**[7](index=7&type=chunk) [UnitedHealthcare Segment](index=3&type=section&id=UnitedHealthcare%20Segment) [Overview and 2025 Outlook](index=3&type=section&id=Overview%20and%202025%20Outlook) UnitedHealthcare provides global health care benefits, aiming to improve value, quality, and affordability, with 2025 expectations of revenues between $344.0 billion and $345.5 billion, operating earnings between $9.0 billion and $9.3 billion, and an anticipated increase of up to 1.135 million people served with medical benefits, primarily in senior and complex needs categories UnitedHealthcare 2025 Outlook | UnitedHealthcare 2025 Outlook | Revenues | Operating Earnings | Operating Margin | | :--- | :--- | :--- | :--- | | Employer & Individual | $79,600 - $80,100 | | | | Medicare & Retirement | $170,200 - $170,700 | | | | Community & State | $94,200 - $94,700 | | | | Total UnitedHealthcare Revenue | $344,000 - $345,500 | $9,000 - $9,300 | 2.6% - 2.7% | | UnitedHealthcare People Served | Growth in People Served | Total People Served | | | Total Medical | 1,135 | 50,480 | | - Full year **2025** revenues for UnitedHealthcare are expected to grow over **15%** from **2024**, ranging from **$344.0 billion** to **$345.5 billion**[10](index=10&type=chunk) - The number of people served with medical benefits is expected to increase by up to **1.135 million** over **2024**, led by serving seniors and people with complex needs[10](index=10&type=chunk) [Second Quarter 2025 Business Results](index=4&type=section&id=Second%20Quarter%202025%20Business%20Results) UnitedHealthcare's Q2 2025 revenue grew 17% year-over-year to $86.1 billion, serving 50 million people, but operating earnings significantly declined to $2.1 billion, with the operating margin falling to 2.4%, primarily due to higher-than-expected medical cost trends across businesses and Medicare funding reductions UnitedHealthcare Quarterly Financial Performance | Quarterly Financial Performance | June 30, 2025 | June 30, 2024 | March 31, 2025 | | :--- | :--- | :--- | :--- | | Revenues | $86.1 billion | $73.9 billion | $84.6 billion | | Earnings from Operations | $2.1 billion | $4.0 billion | $5.2 billion | | Operating Margin | 2.4% | 5.4% | 6.2% | - UnitedHealthcare's **Q2 2025** revenue grew **$12.2 billion** or **17%** year-over-year to **$86.1 billion**, serving **50 million** people[12](index=12&type=chunk) - **Q2 2025** operating earnings for UnitedHealthcare were **$2.1 billion**, down from **$4.0 billion** in **Q2 2024**, with operating margin declining to **2.4%** (vs. **5.4%** YoY) due to higher medical cost trends and Medicare funding reductions[12](index=12&type=chunk) [Employer & Individual](index=4&type=section&id=Employer%20%26%20Individual) UnitedHealthcare Employer & Individual revenues increased to $19.8 billion in Q2 2025, driven by commercial offerings, and the number of people served grew by 400,000 year-over-year, primarily from employer self-funded offerings, despite attrition in individual and group fully-insured products - UnitedHealthcare Employer & Individual **Q2 2025** revenues were **$19.8 billion**, up from **$19.2 billion** in **Q2 2024**, driven by commercial offerings[12](index=12&type=chunk) - People served in this segment increased by **400,000** year-over-year, with growth in employer self-funded offerings (**695,000**) partially offset by attrition in individual and group fully-insured products[12](index=12&type=chunk) [Medicare & Retirement](index=4&type=section&id=Medicare%20%26%20Retirement) UnitedHealthcare Medicare & Retirement revenues grew 22% year-over-year to $42.6 billion in Q2 2025, primarily due to Part D IRA impacts and growth in people served, with individual and group Medicare Advantage offerings seeing significant growth, while Medicare Supplement and Standalone Part D plans contracted - UnitedHealthcare Medicare & Retirement **Q2 2025** revenues of **$42.6 billion** grew **$7.7 billion** or **22%** year-over-year, driven by Part D IRA impacts and growth in people served[12](index=12&type=chunk) - People served with individual and group Medicare Advantage offerings grew **505,000** through the first half of **2025**[12](index=12&type=chunk) - Medicare Supplement contracted by **30,000** and Standalone Part D plans decreased by **250,000** through the first half of **2025**[12](index=12&type=chunk) [Community & State](index=4&type=section&id=Community%20%26%20State) UnitedHealthcare Community & State revenues increased 20% year-over-year to $23.7 billion in Q2 2025, driven by growth in serving people with complex needs and Medicaid rate improvements, with members served growing by 55,000 through the first half of 2025 - UnitedHealthcare Community & State **Q2 2025** revenues of **$23.7 billion** grew **20%** year-over-year, driven by growth in serving people with complex needs and Medicaid rate improvements[12](index=12&type=chunk) - Members served grew by **55,000** through the first half of **2025** to a total of **7.5 million** people[12](index=12&type=chunk) [Optum Segment](index=5&type=section&id=Optum%20Segment) [Overview and 2025 Outlook](index=5&type=section&id=Overview%20and%202025%20Outlook) Optum, UnitedHealth Group's health services business, aims to improve health system performance through technology and data, with 2025 expectations of total revenues between $266.0 billion and $267.5 billion and operating earnings between $12.55 billion and $12.85 billion, though the CEO acknowledged that Optum's performance has not met expectations and is refocusing on fundamental execution Optum 2025 Outlook ($ in millions) | Optum 2025 Outlook ($ in millions) | Revenues | Operating Earnings | Operating Margin | | :--- | :--- | :--- | :--- | | Optum Health | $101,100 - $101,600 | $3,000 - $3,100 | 3.0% - 3.1% | | Optum Insight | $19,000 - $19,500 | $3,550 - $3,650 | 18.2% - 19.2% | | Optum Rx | $151,000 - $151,500 | $6,000 - $6,100 | 4.0% | | Eliminations | ($5,100) | | | | Total Optum | $266,000 - $267,500 | $12,550 - $12,850 | 4.7% - 4.8% | - Optum's CEO stated that performance has not met expectations and the focus is on fundamental execution to improve the health system[14](index=14&type=chunk) - Full year **2025** Optum Rx revenues are expected to be **$151.0 billion** to **$151.5 billion**, a significant increase from **$133.2 billion** a year ago, driven by strong customer growth[17](index=17&type=chunk) [Second Quarter 2025 Business Results](index=6&type=section&id=Second%20Quarter%202025%20Business%20Results) Optum's Q2 2025 revenue increased to $67.2 billion, but earnings from operations decreased to $3.1 billion, and the operating margin declined to 4.6%, with performance varying across its sub-segments, as Optum Health experienced a revenue decline, while Optum Insight and Optum Rx showed revenue growth Optum Quarterly Financial Performance | Quarterly Financial Performance | June 30, 2025 | June 30, 2024 | March 31, 2025 | | :--- | :--- | :--- | :--- | | Revenues | $67.2 billion | $62.9 billion | $63.9 billion | | Earnings from Operations | $3.1 billion | $3.9 billion | $3.9 billion | | Operating Margin | 4.6% | 6.2% | 6.1% | - Optum's **Q2 2025** revenue was **$67.2 billion**, an increase from **$62.9 billion** in **Q2 2024**[19](index=19&type=chunk) - **Q2 2025** earnings from operations for Optum were **$3.1 billion**, down from **$3.9 billion** in **Q2 2024**, with operating margin at **4.6%** (vs. **6.2%** YoY)[19](index=19&type=chunk) [Optum Health](index=6&type=section&id=Optum%20Health) Optum Health's Q2 2025 revenue decreased 7% year-over-year to $25.2 billion, primarily due to legacy customer contract revisions and Medicare Advantage funding cuts, with operating earnings significantly declining to $636 million and margins at 2.5%, impacted by higher medical care activity and underpriced health plan offerings - Optum Health's **Q2 2025** revenue of **$25.2 billion** decreased **$1.8 billion** or **7%** year-over-year, driven by legacy customer contract revisions and Medicare Advantage funding cuts[23](index=23&type=chunk) - **Q2 2025** operating earnings were **$636 million** (vs. **$1.9 billion** YoY), with operating margins at **2.5%** (vs. **7.1%** YoY), due to higher medical care activity and underpriced health plan offerings[23](index=23&type=chunk) [Optum Insight](index=6&type=section&id=Optum%20Insight) Optum Insight's Q2 2025 revenue increased 6% year-over-year to $4.8 billion, driven by its diverse portfolio, with operating earnings significantly improving to $998 million and margins at 20.7%, benefiting from reduced impacts of the Change Healthcare cyberattack, a favorable service mix, and improved operating efficiencies, and the contract revenue backlog stood at $32.1 billion - Optum Insight's **Q2 2025** revenue of **$4.8 billion** increased **6%** year-over-year, driven by a diverse portfolio of technology and data-driven offerings[23](index=23&type=chunk) - **Q2 2025** operating earnings were **$998 million** (vs. **$546 million** YoY), with operating margins at **20.7%** (vs. **12.0%** YoY), due to reduced cyberattack impacts, favorable service mix, and improved operating efficiencies[23](index=23&type=chunk) - The contract revenue backlog was **$32.1 billion**[23](index=23&type=chunk) [Optum Rx](index=6&type=section&id=Optum%20Rx) Optum Rx's Q2 2025 revenue increased 19% year-over-year to $38.5 billion, driven by new client growth and existing client expansion, with operating earnings remaining stable at $1.4 billion, but operating margins declining to 3.7% due to increased fulfillment of high-cost drugs and the initial launch of the private label business, and adjusted scripts grew to 414 million - Optum Rx's **Q2 2025** revenue of **$38.5 billion** increased **19%** year-over-year, driven by growth in new clients and expansion in existing client relationships[23](index=23&type=chunk) - Earnings from operations for **Q2 2025** were **$1.4 billion** (stable YoY), but operating margins declined to **3.7%** (vs. **4.3%** YoY) due to higher revenue offset by increased fulfillment of high-cost drugs and the private label business launch[23](index=23&type=chunk) - Adjusted scripts grew to **414 million** compared to **399 million** last year[23](index=23&type=chunk) [Company Information and Disclosures](index=7&type=section&id=Company%20Information%20and%20Disclosures) [About UnitedHealth Group](index=7&type=section&id=About%20UnitedHealth%20Group) UnitedHealth Group operates through two distinct businesses: Optum, which delivers technology and data-aided care, and UnitedHealthcare, which offers a full range of health benefits, with a mission to help people live healthier lives and improve the health system - UnitedHealth Group operates through two complementary businesses: Optum (technology and data-aided care) and UnitedHealthcare (health benefits)[24](index=24&type=chunk) - The company's mission is to help people live healthier lives and make the health system work better for everyone[24](index=24&type=chunk) [Earnings Conference Call](index=7&type=section&id=Earnings%20Conference%20Call) UnitedHealth Group hosted a conference call for investors and analysts on July 29, 2025, at 8:00 a.m. ET to discuss results, strategy, and future outlook, with a webcast replay available on the Investor Relations page until August 12, 2025 - A conference call for investors and analysts was held on **July 29, 2025**, at **8:00 a.m. ET**[25](index=25&type=chunk) - A live webcast and replay are available on the company's Investor Relations website[25](index=25&type=chunk) [Non-GAAP Financial Information](index=7&type=section&id=Non-GAAP%20Financial%20Information) This release includes non-GAAP financial measures, such as adjusted net earnings per share, which are provided as a complement to GAAP results, with reconciliations to the most directly comparable GAAP measures included in the accompanying tables - The news release presents non-GAAP financial information, such as adjusted net earnings per share, as a complement to GAAP results[26](index=26&type=chunk)[49](index=49&type=chunk) - Adjustments include intangible amortization, South American impacts, and direct response costs related to the cyberattack, as these are not considered representative of underlying business performance[49](index=49&type=chunk)[50](index=50&type=chunk)[51](index=51&type=chunk) [Forward-Looking Statements](index=7&type=section&id=Forward-Looking%20Statements) The document contains forward-looking statements subject to various risks and uncertainties, including medical cost management, regulatory changes, cyberattacks, and competitive pressures, where actual results may differ materially from expectations, and the company does not undertake to update these statements except as required by law - The document contains forward-looking statements, identified by words like 'believe,' 'expect,' 'intend,' and 'estimate,' which involve risks and uncertainties[27](index=27&type=chunk) - Actual results could differ materially due to factors such as the ability to manage medical costs, changes in healthcare laws, cyberattacks, and competitive pressures[27](index=27&type=chunk) - The company does not undertake to update or revise any forward-looking statements, except as required by law[28](index=28&type=chunk) [Supplemental Financial Schedules](index=8&type=section&id=Supplemental%20Financial%20Schedules) [2025 Outlook](index=9&type=section&id=2025%20Outlook) This section provides a detailed breakdown of the projected full-year 2025 financial outlook, including revenues and earnings from operations for Optum and UnitedHealthcare, consolidated totals, and key financial ratios such as medical care ratio, operating cost ratio, and tax rate UNITEDHEALTH GROUP SUPPLEMENTAL FINANCIAL INFORMATION - 2025 OUTLOOK | | Projected Year Ended December 31, 2025 | | :--- | :--- | | Revenues: | | | Optum | $266,000 - $267,500 | | UnitedHealthcare | 344,000 - 345,500 | | Eliminations | (164,500) - (165,000) | | Total consolidated revenue | $445,500 - $448,000 | | Earnings from operations: | | | Optum | $12,550 - $12,850 | | UnitedHealthcare | 9,000 - 9,300 | | Total consolidated operating earnings | $21,550 - $22,150 | | Net earnings attributable to UnitedHealth Group common shareholders | At least $13,350 | | Diluted earnings per share attributable to UnitedHealth Group common shareholders | At least $14.65 | | Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a) | At least $16.00 | | Medical care ratio | 89.25% +/- 25 bps | | Operating cost ratio | 12.75% +/- 25 bps | | Operating margin | 4.8% - 5.0% | | Tax rate | ~18.5% | | Cash flows from operations | ~$16,000 | [Condensed Consolidated Statements of Operations](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This statement presents the consolidated revenues, operating costs, earnings from operations, and net earnings for the three and six months ended June 30, 2025, compared to the same periods in 2024, highlighting changes in premiums, products, services, and various cost components Condensed Consolidated Statements of Operations | | Three Months Ended | | Six Months Ended | | | :--- | :--- | :--- | :--- | :--- | | | June 30, 2025 | June 30, 2024 | June 30, 2025 | June 30, 2024 | | Revenues | | | | | | Premiums | $87,905 | $76,897 | $174,439 | $154,885 | | Products | 13,564 | 12,211 | 26,600 | 24,120 | | Services | 9,039 | 8,750 | 18,011 | 17,638 | | Investment and other income | 1,108 | 997 | 2,141 | 2,008 | | Total revenues | 111,616 | 98,855 | 221,191 | 198,651 | | Operating costs | | | | | | Medical costs | 78,585 | 65,458 | 151,996 | 131,193 | | Operating costs | 13,778 | 13,162 | 27,372 | 27,239 | | Cost of products sold | 13,019 | 11,340 | 25,409 | 22,396 | | Depreciation and amortization | 1,084 | 1,020 | 2,145 | 2,017 | | Total operating costs | 106,466 | 90,980 | 206,922 | 182,845 | | Earnings from operations | 5,150 | 7,875 | 14,269 | 15,806 | | Interest expense | (1,027) | (985) | (2,025) | (1,829) | | Loss on sale of subsidiary and subsidiaries held for sale | (41) | (1,225) | (56) | (8,311) | | Earnings before income taxes | 4,082 | 5,665 | 12,188 | 5,666 | | Provision for income taxes | (510) | (1,244) | (2,142) | (2,466) | | Net earnings | 3,572 | 4,421 | 10,046 | 3,200 | | Earnings attributable to noncontrolling interests | (166) | (205) | (348) | (393) | | Net earnings attributable to UnitedHealth Group common shareholders | $3,406 | $4,216 | $9,698 | $2,807 | | Diluted earnings per share attributable to UnitedHealth Group common shareholders | $3.74 | $4.54 | $10.61 | $3.02 | | Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a) | $4.08 | $6.80 | $11.29 | $13.71 | | Diluted weighted-average common shares outstanding | 910 | 928 | 914 | 929 | [Condensed Consolidated Balance Sheets](index=11&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This statement provides a snapshot of the company's financial position as of June 30, 2025, compared to December 31, 2024, detailing assets, liabilities, redeemable noncontrolling interests, and equity Condensed Consolidated Balance Sheets | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Assets | | | | Cash and short-term investments | $32,020 | $29,113 | | Accounts receivable, net | 24,142 | 22,365 | | Other current assets | 37,537 | 34,301 | | Total current assets | 93,699 | 85,779 | | Long-term investments | 52,466 | 52,354 | | Other long-term assets | 162,408 | 160,145 | | Total assets | $308,573 | $298,278 | | Liabilities, redeemable noncontrolling interests and equity | | | | Medical costs payable | $38,427 | $34,224 | | Short-term borrowings and current maturities of long-term debt | 5,698 | 4,545 | | Other current liabilities | 66,656 | 65,000 | | Total current liabilities | 110,781 | 103,769 | | Long-term debt, less current maturities | 73,495 | 72,359 | | Other long-term liabilities | 19,513 | 19,559 | | Redeemable noncontrolling interests | 4,315 | 4,323 | | Equity | 100,469 | 98,268 | | Total liabilities, redeemable noncontrolling interests and equity | $308,573 | $298,278 | [Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This statement outlines the cash flows from operating, investing, and financing activities for the six months ended June 30, 2025, compared to the same period in 2024, showing the net increase in cash and cash equivalents Condensed Consolidated Statements of Cash Flows | | Six Months Ended | | | :--- | :--- | :--- | | | June 30, 2025 | June 30, 2024 | | Operating Activities | | | | Net earnings | $10,046 | $3,200 | | Cash flows from operating activities | 12,644 | 7,890 | | Investing Activities | | | | Cash flows used for investing activities | (1,516) | (13,757) | | Financing Activities | | | | Cash flows (used for) from financing activities | (7,848) | 7,035 | | Net increase in cash and cash equivalents | 3,284 | 859 | | Cash and cash equivalents, end of period | $28,596 | $26,286 | [Supplemental Financial Information - Businesses](index=13&type=section&id=Supplemental%20Financial%20Information%20-%20Businesses) This section provides a detailed breakdown of revenues, earnings from operations, and operating margins for UnitedHealthcare and Optum segments, including their sub-segments, for the three and six months ended June 30, 2025, and 2024 Supplemental Financial Information - Businesses | | Three Months Ended | | Six Months Ended | | | :--- | :--- | :--- | :--- | :--- | | | June 30, 2025 | June 30, 2024 | June 30, 2025 | June 30, 2024 | | Revenues | | | | | | UnitedHealthcare | $86,103 | $73,866 | $170,720 | $149,223 | | Optum | 67,225 | 62,879 | 131,110 | 123,931 | | Total consolidated revenues | $111,616 | $98,855 | $221,191 | $198,651 | | Earnings from Operations | | | | | | UnitedHealthcare | $2,075 | $4,004 | $7,301 | $8,399 | | Optum (a) | 3,075 | 3,871 | 6,968 | 7,407 | | Total consolidated earnings from operations | $5,150 | $7,875 | $14,269 | $15,806 | | Operating Margin | | | | | | UnitedHealthcare | 2.4 % | 5.4 % | 4.3 % | 5.6 % | | Optum | 4.6 % | 6.2 % | 5.3 % | 6.0 % | | Consolidated operating margin | 4.6 % | 8.0 % | 6.5 % | 8.0 % | [Supplemental Financial Information - People Served and Performance Metrics](index=14&type=section&id=Supplemental%20Financial%20Information%20-%20People%20Served%20and%20Performance%20Metrics) This section provides key operational metrics, including the number of people served by UnitedHealthcare across various segments (Commercial, Medicare Advantage, Medicaid, Medicare Supplement) and Optum's performance metrics such as consumers served, contract backlog, and adjusted scripts UnitedHealthcare Customer Profile (in thousands) | People Served | June 30, 2025 | March 31, 2025 | December 31, 2024 | June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Commercial: | | | | | | Risk-based | 8,440 | 8,410 | 8,845 | 8,735 | | Fee-based | 21,530 | 21,590 | 20,885 | 20,835 | | Total Commercial | 29,970 | 30,000 | 29,730 | 29,570 | | Medicare Advantage | 8,350 | 8,245 | 7,845 | 7,770 | | Medicaid | 7,490 | 7,570 | 7,435 | 7,410 | | Medicare Supplement (Standardized) | 4,305 | 4,310 | 4,335 | 4,335 | | Total Community and Senior | 20,145 | 20,125 | 19,615 | 19,515 | | Total UnitedHealthcare - Medical | 50,115 | 50,125 | 49,345 | 49,085 | | Supplemental Data | | | | | | Medicare Part D stand-alone | 2,800 | 2,835 | 3,050 | 3,065 | | South American businesses held for sale | 1,165 | 1,160 | 1,330 | 1,330 | Optum Performance Metrics | Optum Performance Metrics | June 30, 2025 | March 31, 2025 | December 31, 2024 | June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Optum Health Consumers Served (in millions) | 98 | 99 | 100 | 104 | | Optum Insight Contract Backlog (in billions) | $32.1 | $32.9 | $32.8 | $32.6 | | Optum Rx Quarterly Adjusted Scripts (in millions) | 414 | 408 | 422 | 399 | [Reconciliation of Non-GAAP Financial Measure](index=15&type=section&id=Reconciliation%20of%20Non-GAAP%20Financial%20Measure) This section provides a reconciliation of adjusted net earnings per share, a non-GAAP financial measure, to the most directly comparable GAAP measure, detailing adjustments for intangible amortization, South American impacts, and direct response costs related to the Change Healthcare cyberattack, explaining why these exclusions provide a more useful comparison of underlying business performance - Adjusted net earnings per share is a non-GAAP financial measure provided to complement GAAP results, with adjustments for intangible amortization, South American impacts, and direct response costs from the cyberattack[49](index=49&type=chunk)[50](index=50&type=chunk)[51](index=51&type=chunk) Reconciliation of Adjusted Net Earnings Per Share | | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Projected Year Ended December 31, 2025 | | :--- | :--- | :--- | :--- | :--- | :--- | | Net earnings attributable to UnitedHealth Group common shareholders | $3,406 | $4,216 | $9,698 | $2,807 | At least $13,350 | | Intangible amortization | 409 | 417 | 826 | 816 | ~1,625 | | Tax effect of intangible amortization | (99) | (103) | (201) | (201) | ~(400) | | South American impacts | — | 1,340 | — | 8,426 | — | | Tax effect of South American impacts | — | (157) | — | (157) | — | | Direct response costs - cyberattack | — | 776 | — | 1,369 | — | | Tax effect of direct response costs - cyberattack | — | (182) | — | (323) | — | | Adjusted net earnings attributable to UnitedHealth Group common shareholders | $3,716 | $6,307 | $10,323 | $12,737 | At least $14,575 | | Diluted earnings per share | $3.74 | $4.54 | $10.61 | $3.02 | At least $14.65 | | Adjusted diluted earnings per share | $4.08 | $6.80 | $11.29 | $13.71 | At least $16.00 |

Core Viewpoint - UnitedHealth Group has experienced a significant decline in stock value, with a nearly 45% drop year-to-date, marking its worst performance since the Great Recession in 2008 [2][4]. Group 1: Stock Performance - The stock has fallen nearly 45% year-to-date, the worst performance since a 54% drop in 2008 [2]. - Historically, UnitedHealth has been a strong performer, typically outperforming the market, with the last significant decline occurring in 2008 [4]. - An investment of $10,000 in 2003 would have grown to $181,000 by 2023, but has now decreased to $101,000 due to the recent decline [5][6]. Group 2: Challenges Facing the Company - UnitedHealth is currently facing multiple challenges, including rising medical costs and uncertainty in the healthcare sector due to potential federal cost-cutting measures [7]. - The Department of Justice is investigating UnitedHealth's billing practices, which could lead to financial repercussions and increased operational costs [8][9]. - Despite generating over $14.4 billion in profit on $400.3 billion in revenue in 2024, investor concerns about long-term growth are impacting stock performance [9]. Group 3: Future Outlook - The company has suspended its outlook for the year and has undergone a CEO change, which adds to the uncertainty surrounding its future [9]. - While the stock is trading at levels not seen since 2020, with a valuation of 12 times its trailing earnings, it may present a buying opportunity for patient investors [10][11].

Core Viewpoint - A class action lawsuit has been filed against UnitedHealth Group Incorporated for allegedly making false and misleading statements regarding its corporate strategy and practices, which led to investor losses during the specified class period [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of individuals and entities that purchased UnitedHealth securities between December 3, 2024, and April 16, 2025 [1]. - Investors have until July 7, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against UnitedHealth - The lawsuit claims that UnitedHealth engaged in a corporate strategy of denying health coverage to increase profits and share price [3]. - This strategy allegedly led to regulatory scrutiny and public backlash, culminating in the murder of an individual named Brian Thompson [3]. - Following Thompson's murder, there was significant public animosity towards UnitedHealth, with some individuals celebrating the event and demanding changes in the company's practices [3]. - Despite the backlash, UnitedHealth reportedly maintained unrealistic guidance that did not reflect its changing corporate strategies [3]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading throughout the relevant period, resulting in investor damages when the truth was revealed [3].

Core Insights - UnitedHealth Group (UNH) is expected to report its second-quarter earnings on July 29, with a focus on its Optum platform, which may provide stability amid regulatory challenges and margin pressures in the health insurance sector [1][8] Optum Performance - Optum's diverse business model, encompassing pharmacy services, data analytics, and value-based care, positions UNH advantageously. In Q2 2025, Optum's revenues are projected to increase by 7.3% year-over-year, building on a 12% growth in 2024 and a 4.6% growth in Q1 2025 [2][8] - OptumHealth is enhancing its value-based care model, which aims to improve health outcomes while controlling costs, thereby mitigating the impact of rising claims in the sector [3] - OptumInsight is leveraging technology and data-driven services to enhance operational efficiencies for both external clients and UNH itself [3] Competitive Landscape - Elevance Health Inc (ELV) reported a 36.1% year-over-year increase in operating revenues for its Carelon services brand in Q2 2025, while overall operating revenues rose by 14.3% [5] - Cigna's health services division, Evernorth, saw adjusted revenues climb by 16% year-over-year in Q1 2025, with its second-quarter results expected on July 31 [6] Valuation and Earnings Estimates - UNH shares have declined by 44.5% year-to-date, compared to a 36.7% decline in the industry [7] - The forward price-to-earnings ratio for UNH is 12.2, above the industry average of 11.2, with a Value Score of A [9] - The Zacks Consensus Estimate for UNH's 2025 earnings is $21.15 per share, indicating a 23.5% decrease from the previous year [10]

Core Points - The article discusses a class action lawsuit against UnitedHealthcare, alleging predatory practices and Medicare Advantage fraud, highlighting the serious implications for vulnerable populations' access to healthcare [1][4] - The lawsuit claims that UnitedHealthcare misled seniors into abandoning their Original Medicare benefits for profit-driven Medicare Advantage plans, which the company refers to as "Medicare-Disadvantage" plans [1][4] - The case emphasizes the need for accountability and protection for seniors from deceptive marketing practices that could lead to loss of Medicare benefits [2][3] Summary by Sections Allegations and Legal Proceedings - The lawsuit, titled The Estate of Bibi Ahmad v. UnitedHealth Group Inc., was filed in the U.S. District Court for the Central District of California, alleging systemic and predatory advertising practices by UnitedHealthcare [1] - The court dismissed the case on "preemption" grounds but acknowledged the seriousness of the allegations regarding access to healthcare for vulnerable populations [1][4] - The anticipated appeal to the Ninth Circuit aims to reinstate the case for further proceedings, focusing on whether federal CMS regulations exceeded congressional authorization post-Chevron [6] Impact on Seniors - The article highlights the case of a 96-year-old cancer patient, D.D., who was misled into giving up her Medicare benefits, resulting in delayed treatment and unpaid medical bills [5] - The lawsuit claims that UnitedHealthcare's misleading advertising affected hundreds of thousands of seniors nationwide, particularly in California [6] Corporate Practices and Financial Performance - UnitedHealthcare reported over $22.3 billion in profits in 2023, raising concerns about corporate greed and the impact of denied medical claims on seniors [3] - The lawsuit alleges that UnitedHealthcare's advertising misrepresented its Medicare Advantage plans as supplements to Original Medicare, which was not the case [4]